Affordable treatment and political commitment are crucial to eliminate hepatitis C globally.
作者信息
Hellard Margaret, Pedrana Alisa, Draper Bridget
机构信息
Disease Elimination Program, Burnet Institute, Melbourne 3004, VIC, Australia; Department of Infectious Diseases, The Alfred Hospital, Melbourne, VIC, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Doherty Institute and School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.
Disease Elimination Program, Burnet Institute, Melbourne 3004, VIC, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
出版信息
Lancet Gastroenterol Hepatol. 2021 Jun;6(6):414-416. doi: 10.1016/S2468-1253(21)00135-7. Epub 2021 Apr 16.
Abstract
摘要
相似文献
1
Affordable treatment and political commitment are crucial to eliminate hepatitis C globally.可负担的治疗和政治承诺对于在全球消除丙型肝炎至关重要。
Lancet Gastroenterol Hepatol. 2021 Jun;6(6):414-416. doi: 10.1016/S2468-1253(21)00135-7. Epub 2021 Apr 16.
2
Hepatitis C virus screening to reveal a better picture of infection.丙型肝炎病毒筛查揭示更清晰的感染图景。
Trends Microbiol. 2015 Jun;23(6):324-6. doi: 10.1016/j.tim.2015.02.007.
3
Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis.代偿期肝硬化丙型肝炎病毒治疗后骨骼肌质量的改善。
Intern Med. 2021;60(5):745-750. doi: 10.2169/internalmedicine.6029-20. Epub 2021 Mar 1.
4
The Road to Hepatitis C Virus Cure: Practical Considerations from a Health System's Perspective.丙型肝炎病毒治愈之路：从卫生系统角度的实际考虑。
Infect Dis Clin North Am. 2018 Jun;32(2):481-493. doi: 10.1016/j.idc.2018.02.007.
5
Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.达卡他韦：一种用于丙型肝炎感染的NS5A复制复合体抑制剂。
Ann Pharmacother. 2016 Jan;50(1):39-46. doi: 10.1177/1060028015610342. Epub 2015 Oct 20.
6
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.直接作用抗病毒药物治疗完成后慢性丙型肝炎基因型 2 感染患者的真实世界疗效。
Kaohsiung J Med Sci. 2021 Apr;37(4):334-345. doi: 10.1002/kjm2.12315. Epub 2020 Nov 5.
7
Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency.索磷布韦联合 NS5A 抑制剂治疗伴有严重肾功能不全的丙型肝炎病毒感染。
J Viral Hepat. 2018 Dec;25(12):1501-1506. doi: 10.1111/jvh.12983. Epub 2018 Sep 11.
8
Clearance of Hepatitis C Virus After Fixed-Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis.固定剂量组合药物来迪派韦/索磷布韦治疗失代偿期肝硬化青春期女性后丙型肝炎病毒的清除情况
J Pediatr Gastroenterol Nutr. 2016 Nov;63(5):516-517. doi: 10.1097/MPG.0000000000001278.
9
A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.索磷布韦联合NS5A抑制剂治疗丙型肝炎病毒2型慢性感染患者疗效的回顾性研究。
Eur J Gastroenterol Hepatol. 2019 Mar;31(3):382-388. doi: 10.1097/MEG.0000000000001299.
10
Hepatitis C.丙型肝炎
BMJ. 2017 Jul 6;358:j2861. doi: 10.1136/bmj.j2861.
引用本文的文献
1
Alternative Pharmaceutical Innovation Models in Competitive Markets: A Collaborative Approach to Develop a Novel Drug for Hepatitis C.竞争市场中的替代药物创新模式：开发丙型肝炎新药的协作方法
Trop Med Infect Dis. 2024 Oct 8;9(10):233. doi: 10.3390/tropicalmed9100233.
2
Pathway to global elimination of hepatitis B: HBV cure is just the first step.迈向全球消除乙型肝炎之路：HBV 治愈仅仅是第一步。
Hepatology. 2023 Sep 1;78(3):976-990. doi: 10.1097/HEP.0000000000000430. Epub 2023 May 1.
本文引用的文献
1
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.拉维达韦联合索磷布韦治疗无肝硬化或代偿期肝硬化的慢性丙型肝炎感染患者的疗效和安全性（STORM-C-1）：一项两阶段、开放标签、多中心、单臂、2/3 期临床试验的中期分析。
Lancet Gastroenterol Hepatol. 2021 Jun;6(6):448-458. doi: 10.1016/S2468-1253(21)00031-5. Epub 2021 Apr 16.
2
Global hepatitis C elimination: an investment framework.全球丙型肝炎消除：投资框架。
Lancet Gastroenterol Hepatol. 2020 Oct;5(10):927-939. doi: 10.1016/S2468-1253(20)30010-8. Epub 2020 Jul 27.
3
A model of the economic benefits of global hepatitis C elimination: an investment case.全球丙型肝炎消除的经济效益模型：投资案例。
Lancet Gastroenterol Hepatol. 2020 Oct;5(10):940-947. doi: 10.1016/S2468-1253(20)30008-X. Epub 2020 Jul 27.
4
Global timing of hepatitis C virus elimination in high-income countries.高收入国家丙型肝炎病毒消除的全球时间表。
Liver Int. 2020 Mar;40(3):522-529. doi: 10.1111/liv.14324. Epub 2019 Dec 23.
5
Innovative strategies for the elimination of viral hepatitis at a national level: A country case series.国家层面消除病毒性肝炎的创新策略：一个国家案例系列。
Liver Int. 2019 Oct;39(10):1818-1836. doi: 10.1111/liv.14222. Epub 2019 Sep 4.
6
Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4.雷迪帕韦加索磷布韦在初治及经治的基因4型慢性丙型肝炎患者中的疗效
J Hepatol. 2017 Sep 19. doi: 10.1016/j.jhep.2017.09.006.
Zotero 插件